Terms ending in 2044
Every in-force patent on Pfizer Inc.'s record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,758,554 | Stable Immediate Release Tablet and Capsule Formulations of 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 12,281,127 | Pyrido[4,3-d]pyrimidine Compounds In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | |
| US 12,760,019 | Novel SIK Inhibitors In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 12,655,157 | SPIRO[BENZO[D]THIAZOLE-6 ,4'- Piperidine as Acc Inhibitors In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 12,637,461 | Compounds for the Activation of Ampk In force · High confidence | Pfizer Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.